Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Allogeneic hematopoietic stem cell transplantation for myelofibrosis; Patterns, treatment and outcome after relapse and long-term follow up.

View Full Paper
Ask AI
Bookmark
Share

Authors

IDIvetta Danylesko

Discussion

Loading...

Member takes

Overview

Retrospective analysis highlights myelofibrosis outcomes post-HSCT, indicating risks of relapse and late mortality.

Key Points

  • Long-term survival can be achieved in patients with myelofibrosis through allogeneic HSCT, but risks of late relapse persist.
  • The analysis included 102 patients, with an overall survival estimate of 48% at ten years after HSCT.
  • The approach involved a retrospective analysis to evaluate relapse patterns and outcomes following transplant.
  • The findings support the potential effectiveness of HSCT in managing myelofibrosis, noting risks related to Graft-versus-host disease.

Cite This Study

Ivetta Danylesko (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da23https://doi.org/10.1182/blood-2025-6054
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Haplo-identical transplantation in patients with myelofibrosis, a phase 2 prospective multicentric study2025
  2. 2Long-term outcome and risk factors for relapse after allogeneic hematopoietic stem cell transplantation in myelofibrosis: Results from a large multicenter cohort2025
  3. 3An evolving landscape – how changing conditioning regimes can improve myelofibrosis transplant outcomes.2025
  4. 4Good report of secondary allogeneic hematopoietic stem cell transplantation in patients with refractory/relapsed Acute Myeloid Leukemia2025
  5. 5Long-term outcomes of CML patients undergoing hematopoietic stem cell transplantation in the era of tyrosine kinase inhibitors2025